Meeting
2024 ASCO Annual Meeting
Real world study of racial disparities associated with toxicities of sacituzumab govitecan.
Authors
Shista Priyadarshini
Penn State Cancer Institute, Hershey, PA
Shista Priyadarshini , Justin Petucci , Avnish Katoch , Vasant Honavar , Monali K. Vasekar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Care Delivery/Models of Care
Track
Care Delivery and Quality Care
Sub Track
Disparities in Care
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 1572)
DOI
10.1200/JCO.2024.42.16_suppl.1572
Abstract #
1572
Poster Bd #
443
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
UGT1A1 *28/*28 genotype and risk of toxicity and disease progression in breast cancer patients treated with sacituzumab govitecan-hziy.
First Author: Megan Wong
Poster
2022 ASCO Annual Meeting
Exposure-response analyses of sacituzumab govitecan (SG) efficacy and safety in patients (pts) with metastatic triple-negative breast cancer (mTNBC).
First Author: Indrajeet Singh
Poster
2014 ASCO Annual Meeting
Acute toxicity in African American and Caucasian patients with adjuvant/neoadjuvant chemotherapy for breast cancer.
First Author: Mansoor Ul Haq
Poster
2024 ASCO Annual Meeting
Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.
First Author: Rachel Occhiogrosso Abelman